
SCR7 pyrazine
CAS No. 14892-97-8
SCR7 pyrazine( SCR7 pyrazine | SCR-7 pyrazine | SCR 7 pyrazine )
Catalog No. M17321 CAS No. 14892-97-8
SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 41 | In Stock |
![]() ![]() |
5MG | 65 | In Stock |
![]() ![]() |
10MG | 111 | In Stock |
![]() ![]() |
25MG | 244 | In Stock |
![]() ![]() |
50MG | 386 | In Stock |
![]() ![]() |
100MG | 557 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSCR7 pyrazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionSCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
-
DescriptionSCR7 pyrazine is an inhibitor of nonhomologous end-joining (NHEJ), enhancing CRISPR-Cas9-mediated homology-directed repair (HDR) in vitro.
-
In VitroSCR7 pyrazine (20-100 μM; 24 hours; MCF7 cells) treatment interferes with NHEJ in cells, leading to accumulation of unrepaired double-strand breaks (DSBs).SCR7 pyrazine treatment shows a dose-dependent decrease in cell proliferation with IC50 values of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM and 50 μM for MCF7, A549, HeLa, T47D, A2780, HT1080 and Nalm6 cells, respectively.In MCF7 cells, SCR7 pyrazine (20, 40 μM) treatment increases phosphorylation of ATM and activates p53, decreases MDM2, BCL2, resulting in activation of proapoptotic proteins, PUMA and BAX. And the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9 cleavage are upregulated in a dose-dependent manner. Western Blot Analysis Cell Line:MCF7 cells Concentration:20 μM, 40 μM, 100 μM Incubation Time:24 hours Result:Showed an increase in levels of gH2AX foci and protein.
-
In VivoSCR7 pyrazine (10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan. Animal Model:BALB/c mice injected with breast adenocarcinoma cells Dosage:10 mg/kg Administration:Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10)Result:Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan.
-
SynonymsSCR7 pyrazine | SCR-7 pyrazine | SCR 7 pyrazine
-
PathwayEndocrinology/Hormones
-
TargetCaMK
-
RecptorDNALigase IV
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number14892-97-8
-
Formula Weight332.38
-
Molecular FormulaC18H12N4OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (300.86 mM)
-
SMILESO=c1[nH]c(=S)[nH]c2c1nc(c1ccccc1)c(n2)c1ccccc1
-
Chemical Name2,3-Dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Srivastava M, et al. Cell. 2012, 151(7), 1474-1487.
molnova catalog



related products
-
SCR7 pyrazine
SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
-
KN-62
KN-62 is a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMK II) with Ki of 900 nM for rat brain CaMK II.
-
Perphenazine
Perphenazine is a typical antipsychotic drug, inhibits 5-HT2A receptor (5-HT2A), Alpha-1A adrenergic receptor (α1A), Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor (H1).